FPI-2265 is a small molecule commercialized by Fusion Pharmaceuticals, with a leading Phase III program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of FPI-2265’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for FPI-2265 is expected to reach an annual total of $178 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FPI-2265 Overview
FPI-2265 is under development for the treatment of metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer. It is administered through intravenous route. The therapeutic candidate comprises a radionuclide targeting cells expressing prostate specific membrane antigen (PSMA).
Fusion Pharmaceuticals Overview
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company which develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059 and FPI-1966. The company’s pipeline products treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. It aslo include mono therapy and combination therapy. Fusion Pharmaceuticals carters its products under brand Keytruda. It has its operations in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
The company reported revenues of (US Dollars) US$2.1 million for the fiscal year ended December 2023 (FY2023), an increase of 41.5% over FY2022. The operating loss of the company was US$99.2 million in FY2023, compared to an operating loss of US$88 million in FY2022. The net loss of the company was US$94.9 million in FY2023, compared to a net loss of US$87.6 million in FY2022.
For a complete picture of FPI-2265’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
